Moderna Inc. announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its updated COVID-19 mRNA vaccine, Spikevax targeting the SARS-CoV-2 LP.8.1 variant, for adults… read more.
Moderna Inc. announced that the FDA has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2… read more.
A known facet of coronavirus biochemistry helps to explain the pathological features of Covid-19 and may have implications for the management of long Covid and other conditions. Failure… read more.
In an analysis of published prospective studies of people of all ages with confirmed SARS-CoV-2 infection who were followed for at least 12 months, pre-existing allergic conditions were… read more.
New research used engineered mice to compare SARS-COV-2 omicron subvariants and found one of them – BA.5 – was more virulent likely due to its ability to rapidly… read more.
Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines. In the current study published in the journal mBIO, researchers… read more.
Electronic cigarette users who tested positive for COVID-19 reported a higher frequency of COVID-19 symptoms than similar patients who don’t vape, researchers reported on Jan.13, 2022 in the Journal… read more.
A new study, published in Nature Communications confirms what many people have suspected for a long time – namely that previous human coronavirus infection e.g. with the common cold, could… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
